Home > Research > Publications & Outputs > Preparation of Tc-99m-macroaggregated albumin f...

Research

Links

Text available via DOI:

Keywords

View graph of relations

Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging. / Hunt, Amelia; Frier, M; Johnson, RA et al.
In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 62, No. 1, 01.01.2006, p. 26-31.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Hunt, A, Frier, M, Johnson, RA, Berezenko, S & Perkins, AC 2006, 'Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging', European Journal of Pharmaceutics and Biopharmaceutics, vol. 62, no. 1, pp. 26-31. https://doi.org/10.1016/j.ejpb.2005.06.005

APA

Hunt, A., Frier, M., Johnson, RA., Berezenko, S., & Perkins, AC. (2006). Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging. European Journal of Pharmaceutics and Biopharmaceutics, 62(1), 26-31. https://doi.org/10.1016/j.ejpb.2005.06.005

Vancouver

Hunt A, Frier M, Johnson RA, Berezenko S, Perkins AC. Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging. European Journal of Pharmaceutics and Biopharmaceutics. 2006 Jan 1;62(1):26-31. doi: 10.1016/j.ejpb.2005.06.005

Author

Hunt, Amelia ; Frier, M ; Johnson, RA et al. / Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging. In: European Journal of Pharmaceutics and Biopharmaceutics. 2006 ; Vol. 62, No. 1. pp. 26-31.

Bibtex

@article{9f35dff1ff5b48beaf8a3f7dac9f1f78,
title = "Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging",
abstract = "Human serum albumin (HSA) extracted from pooled blood taken from human donors is used in the production of Tc-99m-labelled macroaggregated albumin (MAA) for lung perfusion imaging. However, concerns for the safety of blood-derived products due to potential contamination by infective agents (e.g. new variant CJD), make alternative production methods necessary. Recombinant DNA technology is a promising method of albumin production avoiding problems associated with human-derived HSA. This paper presents results comparing MAA prepared from recombinant human albumin (MA, Recombumin (R)) (rMAA) with in-house produced HSA MAA (hMAA) and commercially available MAA (cMAA). Tc-99m-MAA was prepared using previously published production methods by heating a mixture of albumin and stannous chloride in acetate buffer (pH 5.4) at 70 degrees C for 20 min. Parameters investigated include aggregate size, radiolabelling efficiency, radiochemical and aggregate stability at 4 degrees C and in vitro (in whole human blood) at 37 degrees C and biodistribution studies. Results showed that rMAA could be produced with similar morphology, labelling efficiency and stability to hMAA and cMAA. Our findings confirm that rHA shows significant potential as a direct replacement for HSA in commercially available MAA. (c) 2005 Elsevier B.V. All rights reserved. ",
keywords = "Serum albumin, Macroaggregates, Recombinant albumin, Lung perfusion, Radiopharmaceutical, Lung imaging, Diagnosis of pulmonary embolism",
author = "Amelia Hunt and M Frier and RA Johnson and S Berezenko and AC Perkins",
year = "2006",
month = jan,
day = "1",
doi = "10.1016/j.ejpb.2005.06.005",
language = "English",
volume = "62",
pages = "26--31",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging

AU - Hunt, Amelia

AU - Frier, M

AU - Johnson, RA

AU - Berezenko, S

AU - Perkins, AC

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Human serum albumin (HSA) extracted from pooled blood taken from human donors is used in the production of Tc-99m-labelled macroaggregated albumin (MAA) for lung perfusion imaging. However, concerns for the safety of blood-derived products due to potential contamination by infective agents (e.g. new variant CJD), make alternative production methods necessary. Recombinant DNA technology is a promising method of albumin production avoiding problems associated with human-derived HSA. This paper presents results comparing MAA prepared from recombinant human albumin (MA, Recombumin (R)) (rMAA) with in-house produced HSA MAA (hMAA) and commercially available MAA (cMAA). Tc-99m-MAA was prepared using previously published production methods by heating a mixture of albumin and stannous chloride in acetate buffer (pH 5.4) at 70 degrees C for 20 min. Parameters investigated include aggregate size, radiolabelling efficiency, radiochemical and aggregate stability at 4 degrees C and in vitro (in whole human blood) at 37 degrees C and biodistribution studies. Results showed that rMAA could be produced with similar morphology, labelling efficiency and stability to hMAA and cMAA. Our findings confirm that rHA shows significant potential as a direct replacement for HSA in commercially available MAA. (c) 2005 Elsevier B.V. All rights reserved.

AB - Human serum albumin (HSA) extracted from pooled blood taken from human donors is used in the production of Tc-99m-labelled macroaggregated albumin (MAA) for lung perfusion imaging. However, concerns for the safety of blood-derived products due to potential contamination by infective agents (e.g. new variant CJD), make alternative production methods necessary. Recombinant DNA technology is a promising method of albumin production avoiding problems associated with human-derived HSA. This paper presents results comparing MAA prepared from recombinant human albumin (MA, Recombumin (R)) (rMAA) with in-house produced HSA MAA (hMAA) and commercially available MAA (cMAA). Tc-99m-MAA was prepared using previously published production methods by heating a mixture of albumin and stannous chloride in acetate buffer (pH 5.4) at 70 degrees C for 20 min. Parameters investigated include aggregate size, radiolabelling efficiency, radiochemical and aggregate stability at 4 degrees C and in vitro (in whole human blood) at 37 degrees C and biodistribution studies. Results showed that rMAA could be produced with similar morphology, labelling efficiency and stability to hMAA and cMAA. Our findings confirm that rHA shows significant potential as a direct replacement for HSA in commercially available MAA. (c) 2005 Elsevier B.V. All rights reserved.

KW - Serum albumin

KW - Macroaggregates

KW - Recombinant albumin

KW - Lung perfusion

KW - Radiopharmaceutical

KW - Lung imaging

KW - Diagnosis of pulmonary embolism

U2 - 10.1016/j.ejpb.2005.06.005

DO - 10.1016/j.ejpb.2005.06.005

M3 - Journal article

VL - 62

SP - 26

EP - 31

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 1

ER -